Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-25 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-25	DKK 8.400	-3.45%	204,929
26-09-24	DKK 8.700	-5.43%	40,017
26-09-23	DKK 9.200	+2.22%	34,384
26-09-22	DKK 9.000	-2.39%	52,703
26-09-21	DKK 9.220	-4.75%	40,933

End-of-day quote NORDIC GROWTH MARKET

More quotes

Net sales - Rate of surprise

Company calendar

End-of-day quote NORDIC GROWTH MARKET 2026-09-25			5-day change	1st Jan Change
8.400 ^DKK	-3.45%		-13.22%	-24.32%

09-14	Curasight co-founders and CEO consolidate ownership in new holding company	FW
08-27	Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	415M 63.34M 55.58M 52.5M 47.84M 89.55M 6.07B 90.19M 628M 243M 3.1B 238M 233M 9.97B	P/E 2024	-4.92x	P/E 2025	-10.1x
Enterprise Value	405M 61.69M 54.13M 51.12M 46.59M 87.22M 5.91B 87.84M 612M 237M 3.02B 232M 227M 9.71B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	64.98%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
NORDIC GROWTH MARKET	CURAS	End-of-day quote
Deutsche Boerse AG	CUS	Delayed

09-14	Curasight co-founders and CEO consolidate ownership in new holding company	FW
08-27	Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-27	Curasight reports a narrower operating loss, pushes clinical data presentation to H1 2027	FW
07-27	Curasight A/S Announces Protocol Amendment to Ongoing Phase I Clinical Trial Evaluating UTREAT In Patients with Glioblastoma	CI
07-27	Curasight seeks to change the design of Phase 1 study	FW
06-23	Curasight raises DKK 20m in a directed share issue	FW
06-08	Curasight Announces Preliminary Readout from Phase 1 Clinical Trial with uTREAT In Aggressive Brain Cancer	CI
06-08	Curasight reports promising Phase 1 data in aggressive brain cancer	FW
05-28	Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-28	Curasight reports widening losses	FW
04-27	Shareholder reshuffle at Curasight following restructuring	FW
03-25	Curasight A/S Announces Board Changes	CI
03-09	Curasight reduces debt following loan conversion	FW

Curasight A/S Stock

Stocks

CURAS

DK0061295797

Biotechnology & Medical Research

Valuation: Curasight A/S

Chart: Curasight A/S

Latest news: Curasight A/S

Analysts' recommendations: Curasight A/S

Press Releases: Curasight A/S

Quotes and Performance

Price Extremes

Managers and Directors: Curasight A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Net sales - Rate of surprise

24-05-27	Redeye lowers motivated value for Curasight after report - lowers OPEX assumptions	FW
24-05-27	Redeye lowers the fair value of Curasight to DKK 27 (29)	FW
24-03-12	Curasight's news was clearly negative - SEB	FW
23-10-25	Curasight rises after Redeye initiates coverage	FW
23-10-25	Redeye initiates coverage of Curasight with motivated value of DKK 29 in the base case	FW

09-14	Major Shareholding Notification - ownership restructuring - related party transaction	AQ
08-28	Curasight: Letting the data guide uTREAT development	AQ
08-27	Curasight publishes Interim Report Q2 2026	AQ
07-27	Curasight: Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)	PU
07-27	Curasight Announces protocol update for the Phase I uTREAT trial in Aggressive Brain Cancer (Glioblastoma)	AQ

1 day	-3.45%
1 week	-13.22%
Current month	-28.51%
1 month	-44.55%
3 months	-58.62%
6 months	-46.67%
Current year	-24.32%

1 week	7.68	11.15
1 month	7.68	13.4
Current year	7.68	25
1 year	3.8	25
3 years	1.8	25
5 years	1.8	32.75
10 years	1.8	44.05

Manager	Title	Age	Since
Jacob Madsen PRN	Corporate Officer/Principal	54	2012-12-31
Ulrich Krasilnikoff CEO	Chief Executive Officer	59	2015-12-31
Andreas Kjær CTO	Chief Tech/Sci/R&D Officer	63	2012-12-31

Director	Title	Age	Since
Andreas Kjær BRD	Director/Board Member	63	2012-12-31
Lars Trolle BRD	Director/Board Member	59	2013-12-31
Charlotte Vedel BRD	Director/Board Member	58	2019-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CURASIGHT A/S	-3.45%	-13.22%	+76.47%	-54.84%	63.34M
LONZA GROUP AG	-0.14%	+4.33%	+9.88%	+31.73%	47.97B
IQVIA HOLDINGS INC.	-1.69%	+1.48%	+53.02%	+33.59%	44.5B
REVOLUTION MEDICINES, INC.	+2.56%	+7.34%	+382.17%	+594.81%	43.93B
BEONE MEDICINES AG	+0.24%	+2.85%	+9.78%	+89.54%	41.03B
CELLTRION, INC.	-0.62%	-1.11%	+4.70%	+46.02%	29.85B
MEDPACE HOLDINGS, INC.	-0.28%	+1.07%	+26.83%	+152.91%	17.27B
EUROFINS SCIENTIFIC SE	-0.46%	+1.20%	+26.78%	+41.32%	15.3B
ASCENDIS PHARMA A/S	-2.21%	-4.70%	-	-	14.82B
TEMPUS AI, INC.	+3.37%	+9.21%	+9.93%	-	15.34B
Average	-0.27%	+1.23%	+66.62%	+116.89%	27.01B
Weighted average by Cap.	+0.11%	+2.86%	+83.03%	+156.16%

	2024	2025
Net sales	-	-
Net income	-36.84M -5.62M -4.93M -4.65M -4.24M -7.94M -538M -8M -55.7M -21.57M -275M -21.09M -20.63M -884M	-53.23M -8.12M -7.12M -6.73M -6.13M -11.47M -778M -11.56M -80.48M -31.17M -397M -30.47M -29.81M -1.28B
Net Debt	911K 139K 122K 115K 105K 196K 13.31M 198K 1.38M 534K 6.8M 521K 510K 21.86M	-10.85M -1.65M -1.45M -1.37M -1.25M -2.34M -159M -2.36M -16.41M -6.36M -81.01M -6.21M -6.08M -260M